Latest Advances in Lung Cancer Research

The FDA has approved a new drug called Datroway (datopotamab deruxtecan) for patients with EGFR-positive non-small cell lung cancer (NSCLC) who have already tried targeted therapy and chemotherapy. This approval marks an important step forward in lung cancer treatment.

Clinical cancer informatics research applying computational methods or digital health technologies to improve cancer care and patient outcomes.

Researchers repurposed MDM2 inhibitor RG7388 as a potential targeted therapy for treating TP53-mutant non-small cell lung cancer patients.

Dr. Ramalingam emphasizes community oncologists must prioritize molecular testing and lung cancer screening to improve patient access to treatments.

Research develops hypoxic gene expression signatures to predict which muscle-invasive bladder cancer patients will respond to hypoxia-modifying therapies.

Leading lung cancer specialists discuss revolutionary advances in treating EGFR-mutated non-small cell lung cancer, highlighting how new combination therapies like amivantamab plus chemotherapy are doubling progression-free survival and offering hope for patients with challenging complications like leptomeningeal metastases, while emphasizing practical strategies for managing treatment side effects in community practice.

Researchers developed RARE-seq, an ultrasensitive blood test detecting cell-free RNA that identifies early-stage lung cancer and monitors treatment resistance.

New drug shrinks HER2-mutant lung cancer tumors in 73% of patients, offering hope for improved treatment options.

Comprehensive review examining molecular mechanisms of cancer invasion and metastasis, identifying potential therapeutic targets for preventing cancer spread.

Final clinical trial results demonstrate selpercatinib’s safety and efficacy in treating RET fusion-positive non-small cell lung cancer patients.

Osimertinib after surgery significantly improves survival in early-stage EGFR-mutated NSCLC, reducing cancer recurrence and offering a new standard of care.

The FDA has approved amivantamab for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.